Megha Manchanda &Amp;Amp; Sohini Das

Stories by Megha Manchanda &Amp;Amp; Sohini Das

'Cipla has emerged as a great catchment area for talent'

'Cipla has emerged as a great "catchment area" for talent'

Rediff.com   20 Aug 2020

An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies.

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Rediff.com   19 Aug 2020

The institute expects to complete both, phase-2 and 3 trials in India by the end of this year.

Covid drug sales shine even as market slows

Covid drug sales shine even as market slows

Rediff.com   18 Aug 2020

Fabiflu sales have grown by 62 per cent in July. It was launched in June. This drug is being used by doctors for mild-to-moderate Covid patients even if they are in home isolation.

Fortis to re-brand itself as Parkway

Fortis to re-brand itself as Parkway

Rediff.com   15 Aug 2020

The company said this was 'important' to reinforce the 'complete disassociation' from its erstwhile promoters -- Malvinder and Shivinder Singh.

How govt plans to distribute Covid-19 vaccine

How govt plans to distribute Covid-19 vaccine

Rediff.com   13 Aug 2020

The procurement and distribution will be centralised though the government is yet to take a call on the initial number of doses that will be procured.

After showing signs of recovery, pharma sales dip in July

After showing signs of recovery, pharma sales dip in July

Rediff.com   11 Aug 2020

Growth has been under pressure since the lockdowns related to Covid-19 started and fresh prescription generations slowed.

Serum Institute to provide Covid vaccine at Rs 250 a dose

Serum Institute to provide Covid vaccine at Rs 250 a dose

Rediff.com   8 Aug 2020

Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.

Meet Adar Poonawala, India's COVID-19 vaccine man

Meet Adar Poonawala, India's COVID-19 vaccine man

Rediff.com   6 Aug 2020

Serum Institute is investing $200 million to create capacities for the COVID-19 vaccine. Sohini Das profiles its 39-year-old CEO.

At Rs 35 a pill, Sun Pharma's FluGuard is the cheapest favipiravir drug

At Rs 35 a pill, Sun Pharma's FluGuard is the cheapest favipiravir drug

Rediff.com   5 Aug 2020

Favipiravir is the only oral anti-viral treatment approved in India for potential treatment of patients with mild to moderate Covid-19 disease.

Dr Reddy's to launch Covid drugs remdesivir and favipiravir in August

Dr Reddy's to launch Covid drugs remdesivir and favipiravir in August

Rediff.com   30 Jul 2020

Apart from favipiravir and remdesivir, its key Covid-19 products, DRL has already launched nutraceutical products and hand sanitisers during the pandemic.

Covid-19: Testing times for plasma banks

Covid-19: Testing times for plasma banks

Rediff.com   30 Jul 2020

While the process of extracting plasma itself is simple, doctors say that it is the screening of donors, testing and filling up of numerous forms that takes time.

'We will price Covid vaccine below Rs 1,000'

'We will price Covid vaccine below Rs 1,000'

Rediff.com   29 Jul 2020

Pune's Serum Institute of India, the world's largest vaccine maker by volume, is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222 with CEO Adar Poonawalla stating he would start manufacturing at personal risk.

COVID-19: Lessons to be learnt from Delhi, Mumbai

COVID-19: Lessons to be learnt from Delhi, Mumbai

Rediff.com   27 Jul 2020

The two cities finally got their act together by ramping up the testing capacity and implementing stricter quarantine norms.

AGR licence fee for wireline broadband may be slashed to Re 1

AGR licence fee for wireline broadband may be slashed to Re 1

Rediff.com   21 Jul 2020

The proposal may provide relief to the tune of Rs 9,000 crore to service providers.

Glenmark's favipiravir under fire for 'misguided' claims of Covid-19 drug

Glenmark's favipiravir under fire for 'misguided' claims of Covid-19 drug

Rediff.com   20 Jul 2020

The Drug Controller General of India has sent a letter to the Glenmark seeking clarifications on pricing as well as claims of therapeutic efficacy. While Glenmark has claimed this drug is effective in comorbid conditions like diabetes, hypertension, according to protocol summary (of clinical trials) the trial was not designed to access the Fabiflu in comorbid conditions.

Why did Iran eject India from port, oil field deals?

Why did Iran eject India from port, oil field deals?

Rediff.com   16 Jul 2020

Iran's growing proximity to China may have also played a part.

Asset sale process for BSNL, MTNL begins

Asset sale process for BSNL, MTNL begins

Rediff.com   16 Jul 2020

Monetising real estate assets is part of the overall relief package that would be used to retire debts, upgrade networks, and offer VRS aimed at reducing the telcos' employee strength by half.

Covaxin launch now depends on clinical sites' deadline

Covaxin launch now depends on clinical sites' deadline

Rediff.com   9 Jul 2020

There are 12 sites across India, including private and public hospitals, conducting Phase 1 and 2 human clinical trials for Bharat Biotech's Covaxin. Based on an earlier letter by the Indian Council of Medical Research (ICMR) to the 12 sites, volunteer recruitments for the clinical trials were to begin by July 7. At least three sites are yet to kick-start the process.

Every 3rd tablet in the US market is from India

Every 3rd tablet in the US market is from India

Rediff.com   9 Jul 2020

India lost its competitive advantage as China gave fiscal benefits to its local manufacturers. Besides, recent policy flip-flops have, however, dented India's image as the 'pharmacy of the world'.

Customs to clear pharma raw materials from China

Customs to clear pharma raw materials from China

Rediff.com   1 Jul 2020

Apart from them, consignments of 11 top importers, including LG, Samsung, Toyota, Honda, and Siemens, will also be allowed entry, relieving them of the 100 per cent inspection rule.